Corey Cutler, MD, MPH, FRCPC
Treatment with the selective ROCK2 inhibitor KD025 led to statistically significant overall response rates (ORRs) in patients with chronic graft-versus-host disease (cGVHD) who have received ≥2 prior lines of systemic therapy, meeting the primary endpoint at an interim analysis of the phase II ROCKstar trial (KD025-213; NCT03640481).1
Cytokines (IL-21, IL-17) regulated by the ROCK2 signaling pathway play an integral role in the pathogenesis of cGVHD. Clinical research has demonstrated that inhibiting the ROCK2 pathway reduces the pathogenesis of cGVHD.
- Kadmon announces that KD025 met primary endpoint at interim analysis of pivotal trial in chronic graft-versus-host disease. Kadmon Holdings, Inc. Published November 11, 2019. https://bit.ly/2pWygUc. Accessed November 12, 2019.
- Lazaryan A, Lee SJ, Salhotra A, et al. Initial results of KD025-208: a phase 2a open-label clinical trial of KD025 for steroid-dependent chronic graft versus host disease (cGVHD). Biol Blood Marrow Transplant. 2018;24(3):S25-S118. doi: 10.1016/j.bbmt.2017.12.615.
... to read the full story